Analyst Rating Update on Radius Health (RDUS)

Radius Health (RDUS) : The consensus on Radius Health (RDUS) based on 7 analyst recommendation on the company stock is 1.57, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 5 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Radius Health (RDUS) : Average target price received by Radius Health (RDUS) is $55 with an expected standard deviation of $13.64. The most aggressive target on the stock is $70, whereas the most downbeat target is $37. 4 financial analysts are currently covering the stock.

For the current week, the company shares have a recommendation consensus of Buy. Also, HC Wainwright initiates coverage on Radius Health (NASDAQ:RDUS) The current rating of the shares is Buy. Equity Analysts at the Firm announces the price target to $55 per share. The rating by the firm was issued on May 23, 2016.


Radius Health (NASDAQ:RDUS): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $50.00 and $49.83 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $56.89. The buying momentum continued till the end and the stock did not give up its gains. It closed at $53.00, notching a gain of 8.21% for the day. The total traded volume was 4,079,552 . The stock had closed at $48.98 on the previous day.

Radius Health, Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, as well as other serious endocrine-mediated diseases. The Companys lead product candidate is abaloparatide (BA058), a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection, which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch, which the Company refers to as abaloparatide-TD. The Companys clinical product portfolio also includes the investigational drug RAD1901, a selective estrogen receptor down regulator/degrader (SERD) and RAD140, a nonsteroidal selective androgen receptor modulator (SARM), for the treatment of breast cancer.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.